These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 29167667)

  • 21. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
    Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
    Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
    Xia B; Qu F; Yuan T; Zhang Y
    Oncol Lett; 2015 Dec; 10(6):3339-3344. PubMed ID: 26788133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton's tyrosine kinase together with PI 3-kinase are part of Toll-like receptor 2 multiprotein complex and mediate LTA induced Toll-like receptor 2 responses in macrophages.
    Liljeroos M; Vuolteenaho R; Morath S; Hartung T; Hallman M; Ojaniemi M
    Cell Signal; 2007 Mar; 19(3):625-33. PubMed ID: 17020802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific binding of the WASP N-terminal domain to Btk is critical for TLR2 signaling in macrophages.
    Sakuma C; Sato M; Takenouchi T; Kitani H
    Mol Immunol; 2015 Feb; 63(2):328-36. PubMed ID: 25213142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect on neutrophil migration and antimicrobial functions by the Bruton's tyrosine kinase inhibitors tolebrutinib, evobrutinib and fenebrutinib.
    De Bondt M; Renders J; de Prado PP; Berghmans N; Pörtner N; Vanbrabant L; de Oliveira VLS; Duran G; Baeten P; Broux B; Gouwy M; Matthys P; Hellings N; Struyf S
    J Leukoc Biol; 2024 Jul; ():. PubMed ID: 38976501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.
    Mohamed AJ; Yu L; Bäckesjö CM; Vargas L; Faryal R; Aints A; Christensson B; Berglöf A; Vihinen M; Nore BF; Smith CI
    Immunol Rev; 2009 Mar; 228(1):58-73. PubMed ID: 19290921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of monoclonal antibodies to Bruton's tyrosine kinase.
    Stewart DM; Kurman CC; Nelson DL
    Hybridoma; 1995 Jun; 14(3):243-6. PubMed ID: 7590786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
    Maas A; Dingjan GM; Grosveld F; Hendriks RW
    J Immunol; 1999 Jun; 162(11):6526-33. PubMed ID: 10352268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
    Horwood NJ; Mahon T; McDaid JP; Campbell J; Mano H; Brennan FM; Webster D; Foxwell BM
    J Exp Med; 2003 Jun; 197(12):1603-11. PubMed ID: 12810683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of BTK signalling in pathogenic microorganism infections.
    Ye B; Zhou C; Guo H; Zheng M
    J Cell Mol Med; 2019 Oct; 23(10):6522-6529. PubMed ID: 31397086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational analysis of the SH2-kinase linker region of Bruton's tyrosine kinase defines alternative modes of regulation for cytoplasmic tyrosine kinase families.
    Guo S; Wahl MI; Witte ON
    Int Immunol; 2006 Jan; 18(1):79-87. PubMed ID: 16291652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
    de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
    Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
    Zorn CN; Keck S; Hendriks RW; Leitges M; Freudenberg MA; Huber M
    Cell Signal; 2009 Jan; 21(1):79-86. PubMed ID: 18848985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
    García-Merino A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
    Chalmers SA; Doerner J; Bosanac T; Khalil S; Smith D; Harcken C; Dimock J; Der E; Herlitz L; Webb D; Seccareccia E; Feng D; Fine JS; Ramanujam M; Klein E; Putterman C
    Sci Rep; 2016 May; 6():26164. PubMed ID: 27192942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives.
    Tan SL; Liao C; Lucas MC; Stevenson C; DeMartino JA
    Pharmacol Ther; 2013 May; 138(2):294-309. PubMed ID: 23396081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
    Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
    J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
    Arneson LC; Carroll KJ; Ruderman EM
    Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
    Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
    J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
    Lindvall JM; Blomberg KE; Väliaho J; Vargas L; Heinonen JE; Berglöf A; Mohamed AJ; Nore BF; Vihinen M; Smith CI
    Immunol Rev; 2005 Feb; 203():200-15. PubMed ID: 15661031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.